UA125700U - ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE - Google Patents

ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE

Info

Publication number
UA125700U
UA125700U UAU201711412U UAU201711412U UA125700U UA 125700 U UA125700 U UA 125700U UA U201711412 U UAU201711412 U UA U201711412U UA U201711412 U UAU201711412 U UA U201711412U UA 125700 U UA125700 U UA 125700U
Authority
UA
Ukraine
Prior art keywords
asparaginate
magnesium
potassium
antiarithmic
potassium deficiency
Prior art date
Application number
UAU201711412U
Other languages
Ukrainian (uk)
Inventor
Олександр Вікторович Доровський
Геннадій Геннадійович Хорунжий
Олег Миколайович Когута
Original Assignee
Товариство З Обмеженою Відповідальністю "Фармацевтична Група "Здоров'Я"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Товариство З Обмеженою Відповідальністю "Фармацевтична Група "Здоров'Я" filed Critical Товариство З Обмеженою Відповідальністю "Фармацевтична Група "Здоров'Я"
Priority to UAU201711412U priority Critical patent/UA125700U/en
Publication of UA125700U publication Critical patent/UA125700U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Фармацевтична композиція для орального застосування у формі антиаритмічного лікарського засобу, що усуває дефіцит магнію і калію, включає як активні компоненти комбінацію магнію аспарагінату тетрагідрату та калію аспарагінату напівгідрату, а також фармацевтично прийнятні допоміжні речовини для забезпечення стабільності, при наступному співвідношенні інгредієнтів (% мас.): активні фармацевтичні компоненти:магнію аспарагінату тетрагідрат33,25-36,75калію аспарагінату напівгідрат33,25-36,75допоміжні речовини:зв'язуюча речовина0,25-5,0солюбілізатор або дезінтегрант1,0-5,0лубрикант та речовина, що сприяє ковзанню0,5-3,0наповнювачрешта.A pharmaceutical composition for oral administration in the form of an antiarrhythmic drug that eliminates magnesium deficiency and potassium includes, as active ingredients, a combination of magnesium asparaginate tetrahydrate and potassium asparaginate hemihydrate, as well as pharmaceutically acceptable auxiliaries for stability, in the following proportions. : active pharmaceutical components: magnesium asparaginate tetrahydrate33,25-36,75 potassium asparaginate hemihydrate33,25-36,75 auxiliary substances: binder0,25-5,0 solubilization op or dezintehrant1,0-5,0lubrykant and a substance that promotes kovzannyu0,5-3,0napovnyuvachreshta.

UAU201711412U 2017-11-21 2017-11-21 ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE UA125700U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201711412U UA125700U (en) 2017-11-21 2017-11-21 ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201711412U UA125700U (en) 2017-11-21 2017-11-21 ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE

Publications (1)

Publication Number Publication Date
UA125700U true UA125700U (en) 2018-05-25

Family

ID=62171199

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201711412U UA125700U (en) 2017-11-21 2017-11-21 ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE

Country Status (1)

Country Link
UA (1) UA125700U (en)

Similar Documents

Publication Publication Date Title
PE20210401A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM
CL2017003209A1 (en) Orodispersible dosing unit containing an estetrol component
CL2017003208A1 (en) Orodispersible dosing unit containing an estetrol component
TW200837074A (en) Extended triterpene derivatives
CY1124914T1 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTEGRATION INHIBITOR
EP2588116A4 (en) Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
EA201992116A1 (en) PHARMACEUTICAL COMPOSITIONS OF FLOROGLUCINOL AND TRIMETHYLFLOROGLUCINOL
FR2878161B1 (en) ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT
MX2021006969A (en) Peptide binder.
EA202190115A1 (en) FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS FOR THEIR PREPARATION
EA201490222A1 (en) COMBINED COMPOSITIONS BASED ON DARUNAVIR
PE20211588A1 (en) COMPOUNDS AND THEIR USES TO RELIEVE SYMPTOMS ASSOCIATED WITH MENOPAUSE
MX2020007760A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability.
CL2019003533A1 (en) Use of vibegron to treat overactive bladder.
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
MX2022006940A (en) Pharmaceutical compositions comprising cabotegravir.
MX2017005163A (en) Onapristone extended-release compositions and methods.
UA125700U (en) ANTIARITHMIC MEANS TO REDUCE MAGNESIUM AND POTASSIUM DEFICIENCY IN THE TABLE
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
RU2013124416A (en) DIINDOLYLMETHANE MEDICINAL PRODUCT AND ITS APPLICATION FOR TREATMENT OF INFLUENZA AND RESPIRATORY VIRAL INFECTIONS
MX2018005345A (en) Pharmaceutical compositions of dimethyl fumarate.
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
NZ769842A (en) Triterpene amine derivatives
AR067320A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES THE COMBINATION OF AN ANTIMICROBIAL AGENT AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF URINARY INFECTIONS
UA123399U (en) PHARMACEUTICAL COMPOSITION OF CHOLINE ALPHOSCERATE IN MEDICINAL FOR ORAL USE